Author

C. A. Keller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

C. A. Ricker· 1 shared G. A. Li· 1 shared H.-I. H. Chen· 1 shared J. F. Shern· 1 shared K. A. Crawford· 1 shared M. M. Cleary· 1 shared M. N. Svalina· 1 shared N. E. Berlow· 1 shared

Activity by Year

2019-2019 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

C. A. Ricker

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MEK1/2 in Rhabdomyosarcoma

K. A. Crawford, M. M. Cleary, C. A. Ricker, M. N. Svalina, J. F. Shern, H.-I. H. Chen, N. E. Berlow, C. A. Keller, G. A. Li

This study evaluates the combination of MEK inhibitor cobimetinib and chemotherapy in rhabdomyosarcoma, finding no significant additive or synergistic effects and potential antagonistic effects on chemotherapy efficacy.

bioRxiv · May 28, 2019 · PreprintCancer Biology